We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Guardion Health Sciences Inc | NASDAQ:GHSI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.25 | 3.25 | 3.27 | 0 | 00:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices, including zip code)
Registrant’s
telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 14, 2024, the Board of Directors (the “Board”) of Guardion Health Sciences, Inc. (the “Company”) approved Amendment No. 2 (the “Amendment”) to the Second Amended and Restated Bylaws of the Company (the “Bylaws”), effective immediately. The Amendment reduced the number of directors of the Company from a range of three to seven directors to a range of one to two directors. The exact number of directors within the range is set, from time to time, by the Board. On November 14, 2024, the Board fixed the number of directors at two.
Effective as of November 14, 2024, Michaela Griggs and Don Gagliano resigned from the Board of the Company, in recognition of the reduced number of directors of the Company pursuant to the Amendment. The resignations of each of Ms. Griggs and Mr. Gagliano was not the result of any disagreement between either Ms. Griggs or Mr. Gagliano and the Company, its management, the Board or any committee of the Board, or with respect to any matter relating to the Company’s operations, policies or practices. As there are no disagreements as contemplated by Item 5.02(a) of Form 8-K, the Company is disclosing this information pursuant to Item 5.02(b) of Form 8-K. The remaining members of the Board are Robert N. Weingarten and Mark Goldstone.
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
The information set forth in Item 5.02 related to the Amendment is incorporated herein by reference.
This description is only a summary of the changes made to the Bylaws pursuant to the Amendment and is qualified in its entirety by reference to the Amendment, which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Exhibit | |
3.1 | Amendment No. 2 to Second Amended and Restated Bylaws. | |
104 | Cover Page Interactive Data File (embedded within the XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 18, 2024 | GUARDION HEALTH SCIENCES, INC. | |
(Registrant) | ||
By: | /s/ Katie Cox | |
Name: | Katie Cox | |
Title: | Chief Accounting Officer |
Exhibit 3.1
AMENDMENT NO. 2 TO
SECOND AMENDED AND RESTATED BYLAWS
OF
GUARDION HEALTH SCIENCES, INC.
a Delaware Corporation
Pursuant to resolutions of the Board of Directors (the “Board”) of Guardion Health Sciences, Inc. a Delaware corporation (the “Corporation”) adopted at a meeting of the Board held on November 14, 2024 and in accordance with the authority provided to the directors pursuant to Article XIII of the Corporation’s Second Amended and Restated Bylaws (the “Bylaws”), Article III, Section 1 of the Bylaws is amended in its entirety as follows as of November 14, 2024 (the “Effective Time”):
“SECTION 1. Number, Qualification and Term of Office. The business, property and affairs of the Corporation shall be managed by a board consisting of not less than one (1) or more than two (2) directors. The Board of Directors shall from time to time by a vote of a majority of the directors then in office fix within the maximum and minimum limits the number of directors to constitute the Board. At each annual meeting of stockholders, a Board of Directors shall be elected by the stockholders for a term of one (1) year. Each Director shall serve until his successor is elected and shall qualify.”
C E R T I F I C A T E O F S E C R E T A R Y
I, the undersigned, do hereby certify:
1. That I am the duly elected and acting secretary of Guardion Health Sciences, Inc., a Delaware corporation; and
2. That the foregoing Amendment No. 2 to the Second Amended and Restated Bylaws, was duly adopted by the board of directors of said corporation on November 14, 2024.
IN WITNESS WHEREOF, I have hereunto subscribed my name and affixed the seal of said Corporation as of November 14, 2024.
/s/ Robert N. Weingarten | |
Robert N. Weingarten, Secretary |
Cover |
Nov. 14, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Nov. 14, 2024 |
Current Fiscal Year End Date | --12-31 |
Entity File Number | 001-38861 |
Entity Registrant Name | GUARDION HEALTH SCIENCES, INC. |
Entity Central Index Key | 0001642375 |
Entity Tax Identification Number | 47-4428421 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 2925 Richmond Avenue |
Entity Address, Address Line Two | Suite 1200 |
Entity Address, City or Town | Houston |
Entity Address, State or Province | TX |
Entity Address, Postal Zip Code | 77098 |
City Area Code | (800) |
Local Phone Number | 873-5141 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |
1 Year Guardion Health Sciences Chart |
1 Month Guardion Health Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions